Skip Navigation

Adalvo announces successful Pilot BE program for Empagliflozin+Metformin

01 March 2023

Adalvo is thrilled to announce that we have successfully completed our Pilot BE program for Empagliflozin+Metformin 12.5mg/1000mg film-coated tablets. This product has been developed in collaboration with one of our strategic partners.

Our product has been developed based on the reference brand Synjardy 12.5mg/1000mg film-coated Tablets, which is indicated in the treatment of type 2 diabetes mellitus.

The brand sold approximately $1.2bn globally in 2021, having a significant growth potential with Global 3Y CAGR at +26%, according to IQVIA.

Based on this successful development, we expect be amongst the first companies to launch on Day-1, in all major markets.

Adalvo is one of the few companies having an extensive offering of both small molecule and peptide treatment possibilities for type 2 diabetes, as depicted below.